Trabectedin for the therapy of ovarian cancer.

• G. Evangelisti ^{[3] [1]} ; F. Barra ^{[3] [1]} ; G. DAlessandro ^{[3] [1]} ; M. Tantari ^{[3] [1]} ; S. Stigliani ^{[3] [1]} ; L. Della Corte ^[2] ; G. Bifulco ^[2] ; S. Ferrero ^{[3] [1]}
  1. [1] University of Genoa

     University of Genoa

     Genoa, Italia

     
  2. [2] University of Naples Federico II

     University of Naples Federico II

     Nápoles, Italia

     
  3. [3] Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

  Mostrar afiliaciones +
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 56, Nº. 10, 2020, págs. 669-688
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Trabectedin is a marine-derivate antitumor drug with a relevant cytotoxic activity and good safety profile. It has been investigated for the treatment of solid diseases, including ovarian cancer (OC), breast cancer, and soft-tissue sarcoma. In 2009, results from the pivotal trial OVA-301 led the European Medicines Agency (EMA) to the approval of trabectedin in combination with PEGylated liposomal doxorubicin for the treatment of platinum-sensitive recurrent OC; further studies revealed an additional benefit also in the subgroup of patients with partially platinum-sensitive disease and in those with a BRCA-mutated status. Additionally, trabectedin demonstrated to prolong the time interval to the subsequent chemotherapy line. Recently, the improved understanding of the antitumor action exerted by trabectedin paved the way to new investigational trials exploring its combination with targeted therapies.